Ambit Biosciences Articles
Novel therapeutic agents presented at ASH provide hope for patients with hard-to-treat blood disorders
11 December 2012
Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug
6 November 2012
Acute myeloid leukemia market to be worth $1.67 billion by 2020
20 December 2011
Showing 1-4 of 4 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
